The content on this site is intended for healthcare professionals only
Strategies to improve the tolerability of treatment in patients with multiple myeloma
Emerging advances in multiple myeloma; expert roundtable at MM CTP 2012
Best treatment for chronic lymphocytic leukaemia with 17p deletion
The involvement of rare cancer patients in clinical research
New drugs on the CML horizon; choosing the correct therapies
The evolving landscape in the management of CML
Maintenance therapy in multiple myeloma; the way forward
A new treatment paradigm in multiple myeloma
Advances with bendamustine in multiple myeloma from EHA 2012
Advances in multiple myeloma from EHA 2012
Advances in multiple myeloma from EHA 2012; bortezomib and beyond
Dasatinib vs. imatinib first-line in CML; new study data
The evolving landscape in CML management
AZA in MDS, and managing the older MDS patient
Lenalidomide in low-risk MDS del(5q)
EHA 2012 advances in lymphoma; lenalidamide and beyond
Identifying drug sensitivity and resistance in acute myeloid leukaemia
Addressing the problem of adherence to treatment
Patient and doctor communication and quality of life guidelines
GFI is crucial for AML1-ETO induced acute myeloid leukemia
Signaling and targeting cellular pathways in leukaemia metabolism
Whole genome sequence analysis for acute lymphoblastic leukaemia
Use of mesenchymal stromal cells against graft-versus-host disease
Next generation sequencing and the monoclonal structure of multiple myeloma
Mouse models and proteomics tackling acute lymphoblastic leukaemia
Assessing iron overload and toxicity
What clinicians believe they said and what patients believe they heard
New drugs for relapsed and refractory Hodgkin's lymphoma
Open Window project improves patient quality of life
How malignant cells in patients with CLL escape T-cell recognition
Reducing radiotherapy for Hodgkin's lymphoma while maintaining the highest cure rate
Impressive results with a bispecific antibody for ALL
Open Window project improves patient quality of life
Acute Lymphocytic Leukemia: impressive results with a bispecific antibody in patients with refractory disease
How malignant cells in patients with CLL escape T-cell recognition
Hodgkin Lymphoma focusing on reducing radiotherapy, while maintaining the highest possible cure rate
